Depressed 5-hydroxyindole levels associated with hyperactive and aggressive behavior. Relationship to drug response

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Hyperactivity in institutionalized mentally retarded patients is a significant clinical challenge.
• Serotonin, indicated by 5-hydroxyindole (5-HI) levels, is a neurotransmitter implicated in various behavioral and neurological functions.

Purpose of the Study:

• To investigate the relationship between blood 5-hydroxyindole (5-HI) levels and hyperactivity in institutionalized mentally retarded patients.
• To determine the effect of psychoactive drug therapy on 5-HI levels and the hyperkinetic syndrome.

Main Methods:

• Monitoring of blood 5-hydroxyindole (5-HI) levels in patients before and after drug therapy.
• Classification of medications based on their effect on 5-HI levels (elevate, lower, no effect).
• Correlation of 5-HI levels with the presence or absence of hyperactivity.

Main Results:

• 83% of hyperactive patients exhibited depressed blood 5-HI levels.
• Normalization of 5-HI levels through psychoactive agents was associated with the resolution of hyperactivity.
• Continued hyperactivity correlated with persistently low 5-HI levels.
• Withdrawal of medication led to a decrease in 5-HI levels and a return of hyperactivity.
• Adverse responses occurred when patients received medications known to lower 5-HI levels.

Conclusions:

• Low blood serotonin (5-HI) levels are strongly associated with hyperactivity in this patient population.
• Modulating 5-HI levels appears to be a key factor in managing the hyperkinetic syndrome.
• Medication choice in treating hyperactivity should consider its impact on 5-HI levels.